期刊文献+

伊立替康联合顺铂时辰化疗治疗小细胞肺癌的临床研究 被引量:4

Chrono-chemotherapy with irinotecan plus cisplatin for small cell lung cancer
暂未订购
导出
摘要 目的比较伊立替康联合顺铂的时辰化疗与常规化疗治疗小细胞肺癌(SCLC)的疗效和不良反应。方法60例非小细胞肺癌患者随机分为两组,时辰组31例予时辰化疗,伊立替康60mg/m2静脉滴注第1、8、15天,于上午02:00开始,至08:00结束,顺铂60mg/m2静脉滴注,第1天,上午10:00开始,至下午22:00结束;对照组29例予常规化疗,每天上午10:00给予伊立替康联合顺铂(两药剂量同时辰化疗组),化疗至少两周期后评价近期疗效。结果时辰化疗组有效率(CR+PR)为87.1%(27/31),常规化疗组有效率为(CR+PR)为65.5%(19/29),两组有效率比较,差异有统计学意义(P<0.05);主要不良反应为血液学毒性、恶心呕吐及延迟性腹泻,时辰化疗组较常规化疗组低(P<0.05)。结论伊立替康联合顺铂时辰化疗治疗小细胞肺癌疗效高于常规化疗,毒副反应轻,值得进一步深入研究。 Objective To compare the efficacy and toxicity of chrono-chemotherapy (irinotecan and cisplatin) with routine - chemotherapy for small cell lung cancer. Methods 60 cases of SCLC patients were randomly grouped ,31 cases for chrono-chemotherapy were treated with irinotecan 60mg/m^2, from 2 : 00AM to 8: AM, cisplatin 60mg/m^2, from 10: 00AM to 22:00PM; and 29 cases were treated with conventional chemotherapy preoceeded on 10AM, For needs of evaluation, all patients must complete at least two cycles. Results The totle response rate (CR+PR) in chrono-chemotherapy and conventional chemotherapy were 87.1% and 65.5% respectively, The difference between two groups had statistical significance, The main adverse events of chemotherapy were leucopenia, gastro intestinal discomfort and delayed diarrhea, the toxicity of chrono-chemotherapy groups were lowed to routine - chemotherapy groups, The difference between two groups had statistical significance. Conclusion The chrono-chemotherapy (irinotecan and cisplatin) was more effective than routine - chemotherapy for small cell lung cancer, and had lower adverse reactions as well. More clinical research should be taken.
出处 《西部医学》 2008年第6期1150-1152,共3页 Medical Journal of West China
基金 四川省卫生厅科研项目(No.050246)
关键词 小细胞肺癌 时辰化疗 伊立替康 顺铂 Small cell lung cancer Chrono-chemotherapy irinotecan Cisplatin
  • 相关文献

参考文献1

二级参考文献7

  • 1Mormont M C ,Cancer,1997年,70卷,2期,241页
  • 2Levi F ,Lancet,1997年,350卷,9079期,681页
  • 3Levi F,Current Opin Oncol,1996年,8卷,4期,334页
  • 4Levi F,Pathol Biol ,1996年,44卷,7期,631页
  • 5Levi F,Bull Cancer,1995年,82卷,29页
  • 6Focan C,Pharmacol Ther,1995年,67卷,1期,1页
  • 7汤钊猷,现代肿瘤学,1993年,598页

共引文献35

同被引文献32

  • 1蒋华,姜维美,刘燕文.时辰化疗与肿瘤患者生活质量关系的研究[J].中华肿瘤防治杂志,2008,15(9):699-702. 被引量:8
  • 2周均田,邬麟,徐建华,胡炳强,殷先利,李旭英,曾毅栋,林荷梅,刘振洋.NP方案时辰化疗治疗非小细胞肺癌的临床研究[J].临床肿瘤学杂志,2007,12(8):583-586. 被引量:12
  • 3孙燕,石远凯.临床肺癌内科手册[M].第5版.北京:人民卫生出版社,2007:147-156.
  • 4Niell HB. Extensive stage small cell lung cancer [J]. Curr Trea Options Oncol, 2001,2(1) : 71.
  • 5吴一龙,蒋国棵,陆舜,等.中国肺癌临床指南[S].北京:第1版.北京:人民卫生出版社,2007:78.
  • 6Horwitz SB. Mechanism o[ action of taxol[J]. Trends Pharmacol Sci, 1992,13(4) : 134.
  • 7Bumm Jr PA. Defining the role of paelitaxel in lung cancel: summary of recent studies and implications for future direetlons[J]. Semin Oncol, 1997,24 (4) : 12.
  • 8Yamamoto N,Tsurutani J, Yoshimura N, et al. Phase II study Of weekly paelitaxel for relapsed and refractory small cell lung cancer [J]. Anticancer Res,2006,26(1B) : 777.
  • 9l.evi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications [J]. Annu Rev Pharmacol Toxicol, 2007,47:593- 628.
  • 10Filipski E,King VM, I.i XM, et al. Host circadian clock as a control point in tumor progression[-J]. Journal of the National Cancer Institute,2002,94(9) :690-697.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部